January 21, 2021
ACC Cardio-oncology Course: The American College of Cardiology will host the annual Advancing the Cardiovascular Care of the Oncology Patient Virtual course with live sessions on Feb. 5-6, 2021, and on demand content. The course will feature cardiology and oncology experts providing clinically relevant, best practice strategies for a multidisciplinary team regarding the assessment, diagnosis and management of cardiovascular concerns for cancer patients, as well as those requiring survivorship care.
ACC Cardio-oncology Course co-directors Ana Barac, MD, Ph.D., FACC, and Bonnie Ky, MD, MSCE, FACC, have invited respected experts in the field to create a course covering relevant and required content for both the novice and advanced practitioner. The conference aims to provide participants with the tools needed to improve patient care in their everyday practice in this rapidly evolving field through describing the evolving advances in immunotherapy and the associated cardiotoxicity; defining cardiovascular complications in cancer patients that are specific to coronary disease, vascular disease and bleeding; applying evidence-based strategies for short- and long-term surveillance; and establishing interprofessional cardio-oncology care teams and a framework to improve overall cardiovascular care of cancer patients and survivors.
- Immune Therapy and Cardiovascular Risk
- Adult and Pediatric Cancer Survivorship: Management of Modifiable Cardiovascular Risk Factors
- All About Amyloidosis
The course will also feature on-demand content available beginning on Monday, January 25, 2021.
The following abstracts are a selection of the posters being presented. All ACC Advancing the Cardiovascular Care of the Oncology Patient abstracts are embargoed until Monday, Jan. 25, 2021 at 8 a.m. ET.
- Cardiovascular Outcomes Associated with Chemotherapy and Targeted Therapies in Adolescent and Young Adult Cancer Survivors
- Cardiovascular Risk Factors and Comorbidities in Male Breast Cancer Patients (press release available)
- Risk of Cardiotoxicity with Dual Human Epidermal Receptor (HER2) Targeted Therapies in Breast Cancer
- The Association of Physical Activity, Cardiac and Patient-Reported Outcomes in HER2+ Breast Cancer Survivors During Therapy